DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L. et al.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
The Lancet 2019;
393: 2599-612
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.